Leeds medtech firm Tissue Regenix has secured a distribution agreement that will see its products sold in Australia and New Zealand.
The maker of biologic grafts suitable for certain ligament reconstruction procedures has signed an exclusive deal with Australian Allografts for distribution of its OrthoPure XT product. As part of the deal, both firms say they are committed to achieving regulatory approval with the Therapeutic Goods Administration - Australia's medicine and therapeutics agency - that will allow them to import and sell the products.
The initial distribution agreement is for three years and requires Australian Allografts to purchase a minimum unit volume each year after achieving approval. Kirsten Lund, EMEA business director for Tissue Regenix, said: "This distribution agreement will allow physicians and patients better access to our innovative products through the Australian Allografts network and is another major step towards Tissue Regenix becoming a global player in the regenerative medicine market. We look forward to working with Australian Allografts."
Read more: £75m salmon farm proposal put to the public as Aquacultured addresses community concern
Andrew Lambing, managing director for Australian Allografts, added: "We are excited to partner with Tissue Regenix, bringing together two organisations with a clear focus for best patient outcome and delivering the latest technologies in tissue development and processing for Australia and New Zealand."
Tissue Regenix's OrthoPure product uses the firm's dCELL technology and is said to be the only available non-human biologic graft for certain anterior cruciate ligament ('ACL') reconstruction procedures on the market. It can also be used in the reconstruction of other knee ligaments.
READ NEXT:
